Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this large retrospective study, patients using compounded topical finasteride and minoxidil through a telehealth platform for male androgenetic alopecia reported high satisfaction and low incidence of side effects, with no need for higher care or treatment discontinuation due to adverse reactions.

This review discusses the use of topical and intralesional corticosteroids for treating alopecia areata, highlighting their efficacy and safety but noting recurrence and pain as limitations; no new clinical results are reported.

This study compared the effectiveness and safety of microneedling with PRP versus minoxidil and finasteride topical therapy in adult males with androgenetic alopecia, finding similar hair density improvements in both groups, though microneedling with PRP had a quicker onset of action.

This study observed that patients using a novel topical combination of finasteride and minoxidil for male androgenetic alopecia reported high satisfaction and good tolerance, with few side effects and no need for higher-level care, despite limitations such as retrospective data and no control group.

This review discusses the substantial impact of alopecia areata on patients' health-related quality of life, highlighting issues such as personality changes, emotional and social difficulties, and a common occurrence of alexithymia, and emphasizes the need for more specific assessment tools.

This study found that individuals with black hair have a significantly higher risk of alopecia areata compared to those with dark brown hair, while lighter hair colors like red or blonde are associated with a lower risk.

This case report describes a male patient with aromatase deficiency, revealing that a c.628G>A mutation can lead to varied clinical features, such as low bone mass and normal metabolic profiles.

This study highlights that shock wave therapy for erectile dysfunction is commonly performed by nonurologists in major U.S. metropolitan areas, with high costs and varied treatment protocols.

This study identified mutations in the SNRPE gene that may disrupt hair growth, linking a spliceosome component to hereditary hair loss disorders.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This study found that patients with severe alopecia areata who experienced meaningful scalp hair regrowth showed greater improvements in health-related quality of life and reduced anxiety and depression compared to those with no or minimal regrowth.

This abstract highlights the urgent need for rigorous research, quality assessment tools, and health economics analyses to integrate DTC telemedicine with traditional primary care for improved healthcare quality and efficiency.

In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.

Female-marketed minoxidil foam is more expensive than male-marketed, but generic and bulk options can reduce this gap.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

In this study, adults with severe alopecia areata experienced greater improvements in hair regrowth, health-related quality of life, and reduced anxiety and depression symptoms after 36 weeks of treatment with baricitinib compared to placebo.

This index of Harper's Textbook of Pediatric Dermatology, Fourth Edition, provides no clinical results or new findings.

This article discusses various limitations of direct-to-consumer teledermatology platforms, highlighting concerns regarding ethical issues, financial conflicts of interest, and challenges in providing comprehensive patient care compared to traditional in-person consultations.

This study provides the first draft of the male Asiatic lion's whole genome, revealing low genomic diversity and highlighting conservation concerns.

In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.

This cross-sectional survey study found that stigmatizing attitudes toward people with alopecia are present in various social and professional settings, with stigma levels varying by alopecia severity and perceptions of its medical nature.

This review of real-world treatment options for AA indicates that current therapies are insufficient, with high dissatisfaction rates, highlighting a need for improved solutions.

This study found that middle-aged patients, patients in certain geographical regions, and female patients of specific age groups with alopecia areata face higher medical costs, indicating significant financial variability for affected subgroups.

This study identified a novel mutation, R430Q in the KRT86 gene, in a Han family with monilethrix, which may contribute to the disease's pathogenic mechanism.

In this study, researchers found that patients with severe alopecia areata often experience reduced health-related quality of life, with significant levels of anxiety and depression, and these mental health impacts may correlate with the severity of their condition.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

This study suggests that sustained hair regrowth is necessary to significantly change patient-reported psychosocial outcomes in alopecia areata, with time since regrowth being a critical factor in measuring adaptation.

In this study, patients with alopecia areata who experienced sustained hair regrowth while being treated with baricitinib showed improvements in health-related quality of life and reductions in anxiety and depression symptoms over 104 weeks, according to the BRAVE-AA phase III trials.

This review highlights the urgent need for increased research and policy support for autoimmune and immune-mediated skin diseases, which are on the rise and disproportionately affect women's health in the United States, suggesting a focus on gender and socioenvironmental factors.

This study found that patients with alopecia areata face challenges like medical uncertainty and lack of information, highlighting the need for reliable and accessible treatment information that aligns with their preferences.